CG Oncology expects PIVOT-006 Phase 3 topline data in the near-term
Company anticipates BLA completion for HR BCG-unresponsive NMIBC in 4Q'26
CG Oncology says cash position sufficient to fund operations through 2029
Result drivers
Clinical trial expenses - Co said higher R&D expenses were primarily due to increased clinical trial activity and CMC costs
Compensation costs - Co attributed increased R&D and G&A expenses to higher compensation costs from increased headcount
Analyst coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for CG Oncology, Inc. is $88.50, about 22.2% above its August 5 closing price of $72.42
Quarterly results
US biopharmaceutical firm's Q2 rev rose to $1.2 mln, reflecting early commercialization activity
Net loss widened to $79.1 mln, driven by higher R&D and G&A expenses
CGON•
